Last Updated on October 17, 2024 by The Health Master
Lupin Limited announced the receipt of the Establishment Inspection Report (EIR) after closure of the US FDA inspection of its Mandideep unit II facility, classifying the inspection as Voluntary Action Indicated (VAI).
The inspection at the facility was carried out by the US FDA between November 26, 2018 and December 4, 2018.
Also read: Caplin gets USFDA approval for generic Naropin injection
Nilesh Gupta, managing director, Lupin said, “We are pleased to have received the EIR for our Mandideep unit II facility, our important cardiovascular API manufacturing facility. We remain committed to enhancing compliance and quality standards across all our manufacturing sites.”
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
